Display options
Cite
Yang Z, Yu Y, Zhang H, et al. Replication priority of hepatitis C virus genotype 2a in a Chinese cohort. Acta Pharm Sin B. 2014;4(4):266-9doi: 10.1016/j.apsb.2014.06.011.
Yang, Z., Yu, Y., Zhang, H., Shang, G., Gao, J., Jiang, J. D., & Peng, Z. (2014). Replication priority of hepatitis C virus genotype 2a in a Chinese cohort. Acta pharmaceutica Sinica. B, 4(4), 266-9. https://doi.org/10.1016/j.apsb.2014.06.011
Yang, Zhen, et al. "Replication priority of hepatitis C virus genotype 2a in a Chinese cohort." Acta pharmaceutica Sinica. B vol. 4,4 (2014): 266-9. doi: https://doi.org/10.1016/j.apsb.2014.06.011
Yang Z, Yu Y, Zhang H, Shang G, Gao J, Jiang JD, Peng Z. Replication priority of hepatitis C virus genotype 2a in a Chinese cohort. Acta Pharm Sin B. 2014 Aug;4(4):266-9. doi: 10.1016/j.apsb.2014.06.011. Epub 2014 Jul 14. PMID: 26579394; PMCID: PMC4629081.
Copy Download .nbib Format: NLM
Share it on

Acta Pharm Sin B. 2014 Aug;4(4):266-9. doi: 10.1016/j.apsb.2014.06.011. Epub 2014 Jul 14.

Replication priority of hepatitis C virus genotype 2a in a Chinese cohort.

Acta pharmaceutica Sinica. B

Zhen Yang, Yongxin Yu, Hongzhong Zhang, Guifang Shang, Jialiang Gao, Jian-Dong Jiang, Zonggen Peng

Affiliations

  1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China ; National Institutes for Food and Drug Control, Beijing 100050, China.
  2. National Institutes for Food and Drug Control, Beijing 100050, China.
  3. Langfang Blood Center, LangFang 065000, China.
  4. Shenzhen Blood Center, Shenzhen 518035, China.
  5. Chengdu Blood Center, Chengdu 610041, China.
  6. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

PMID: 26579394 PMCID: PMC4629081 DOI: 10.1016/j.apsb.2014.06.011

Abstract

HCV genotypes have been documented in clinical practice. The aim of this study was to determine the replication priority of different HCV genotypes in a Chinese HCV positive cohort. Serum samples from 491 apparently healthy Chinese blood donors testing positive for HCV antibodies and naive to antiviral drug therapy were tested. Genotyping analysis showed that genotypes 1b and 2a were predominant and accounted for 77.6% of the HCV infections. Among the genotype groups, individuals infected with genotype 2a had an HCV RNA viral load (10(8) copies/mL) about 200-fold (lg, 2.3) greater than those infected with other genotypes (10(4)-10(5) copies/mL) indicating a replication priority of genotype 2a. However, there was no correlation between HCV genotype and antibody response suggesting that the amplification advantage of genotype 2a results from a favorable interaction with the host cellular environment. In conclusion, HCV genotypes 1b and 2a are the predominant genotypes in China and genotype 2a possesses a significant replication priority compared with the other genotypes. This suggests the existence of host cellular factors that may act as drug-targets for entirely clearing HCV infection in the future.

Keywords: EDTA, ethylenediaminetetraacetic acid; GPT, glutamate-pyruvate transaminase; HCV, hepatitis C virus; NS3, NS4 and NS5, non-structure protein 3, 4 and 5; RdRp, RNA dependent RNA polymerase; SVR, sustained virological response

References

  1. N Engl J Med. 2013 May 16;368(20):1878-87 - PubMed
  2. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2310-5 - PubMed
  3. Curr Top Microbiol Immunol. 2013;369:17-48 - PubMed
  4. Proc Natl Acad Sci U S A. 2006 May 9;103(19):7408-13 - PubMed
  5. Hepatology. 2014 Jan;59(1):318-27 - PubMed
  6. Curr Top Microbiol Immunol. 2013;369:263-88 - PubMed
  7. Clin Drug Investig. 2013 May;33(5):325-31 - PubMed
  8. Clin Infect Dis. 2009 Feb 1;48(3):313-20 - PubMed
  9. Clin Liver Dis. 2011 Aug;15(3):473-82 - PubMed
  10. Adv Pharmacol. 2013;67:169-215 - PubMed
  11. Nat Clin Pract Gastroenterol Hepatol. 2008 Nov;5(11):610-22 - PubMed
  12. J Med Virol. 2005 Apr;75(4):538-49 - PubMed
  13. Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S97-S101 - PubMed
  14. J Med Virol. 2001 Sep;65(1):45-51 - PubMed
  15. Lancet Infect Dis. 2005 Sep;5(9):558-67 - PubMed
  16. Lancet. 2014 Jan 25;383(9914):281 - PubMed
  17. J Hepatol. 2013 Mar;58(3):564-74 - PubMed
  18. Infect Genet Evol. 2012 Mar;12(2):236-9 - PubMed
  19. Biomed Pharmacother. 2009 May;63(4):319-20 - PubMed
  20. Can J Gastroenterol. 2013 Jan;27(1):e8-12 - PubMed

Publication Types